In practice usage of extended-release nitrates in patients with angina in the real-world setting: a clinician’s perspective
DOI:
https://doi.org/10.18203/2320-6012.ijrms20243699Keywords:
Beta-blockers, Headache, Myocardial ischemiaAbstract
Background: Nitrates are highly effective in terminating acute angina pectoris attacks and preventing symptomatic and asymptomatic myocardial ischemia.
Methods: This was an observational survey-based study conducted in cardiologists and physicians with clinical expertise in the management of ischemic heart disease from January 2024 to March 2024. Data entry and statistical analysis were done for completed questionnaires and results are expressed in terms of percentages based on the number of responses obtained.
Results: A total of 47 clinicians participated in this survey. Nitrates were preferred as first-line agents by 59.5% of respondents, while 40.5% favoured beta blockers. Headache (51.0%) was the most common reason for shifting from nitro-glycerine to other anti-anginal. Most clinicians (76.5%) co-prescribed beta blockers with nitrates, while 6.3% co-prescribed calcium channel blockers.
Conclusions: The present survey concluded that nitrates continue to be the preferred anti-angina drugs in the real-world setting in India.
Metrics
References
Gunasekara NS, Noble S. Isosorbide 5-mononitrate: a review of a sustained-release formulation (Imdur) instable angina pectoris. Drugs. 1999;57(2):261-77.
Tarkin JM, Kaski JC. Nicorandil and long-acting nitrates: vasodilator therapies for the management of chronic stable angina pectoris. Eur Cardiol. 2018;13(1):23-8.
Lablanche JM, Bauters C, Leroy F, Bertrand ME. Prevention of coronary spasm by nicorandil: comparison with nifedipine. J Cardiovasc Pharmacol. 1992;20(3):82-5.
Ferrari R, Pavasini R, Camici PG, Crea F, Danchin N, Pinto F, et al. Anti-anginal drugs-beliefs and evidence: systematic review covering 50 years of medical treatment. Eur Heart J. 2019;40(2):190-4.
Silber S. Nitrates: why and how should they be used today? Current status of the clinical usefulness of nitroglycerin, isosorbide dinitrate and isosorbide-5-mononitrate. Eur J Clin Pharmacol. 1990;38(1):35-51.
Olympios C, Stafylas P, Dermitzakis A, Efthimiadis I, Gardikiotis A, Kakouros S, et al. Real-World Data from the Use of Ranolazine in Patients with Stable Angina Pectoris: The RANGER Study. J Clin Med. 2024;13(6):1672.
Thadani U. Role of nitrates in angina pectoris. Am J Cardiol. 1992;70(8):43-53.
Waller DG. Optimal nitrate therapy with a once-daily sustained-release formulation of isosorbide mononitrate. J Cardiovasc Pharmacol. 1999;34(2):29-31.
Parker JO. Eccentric dosing with isosorbide-5-mononitrate in angina pectoris. Am J Cardiol. 1993;72:871-6.
Wood Alastair JJ, Parker, John D, Parker, John O. Nitrate therapy for stable angina pectoris. N Engl J Med. 1998;338(8):520-31.
Qiu Y, Zhou D. Understanding design and development of modified release solid oral dosage forms. J Validation Technol. 2011;17(2):23-32.
Downloads
Published
How to Cite
Issue
Section
